Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 8
2003 10
2004 11
2005 7
2006 6
2007 7
2008 2
2009 6
2010 2
2011 5
2012 4
2013 3
2014 9
2015 6
2016 14
2017 25
2018 17
2019 15
2020 27
2021 25
2022 21
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y, Yoneda M. Sumida Y, et al. Among authors: yoneda m. J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16. J Gastroenterol. 2018. PMID: 29247356 Free PMC article. Review.
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Tokushige K, et al. Among authors: yoneda m. J Gastroenterol. 2021 Nov;56(11):951-963. doi: 10.1007/s00535-021-01796-x. Epub 2021 Sep 17. J Gastroenterol. 2021. PMID: 34533632 Free PMC article. Review.
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Sumida Y, et al. Among authors: yoneda m. Expert Opin Pharmacother. 2020 Jun;21(8):953-967. doi: 10.1080/14656566.2020.1744564. Epub 2020 Apr 1. Expert Opin Pharmacother. 2020. PMID: 32237916 Review.
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Sumida Y, et al. Among authors: yoneda m. Int J Mol Sci. 2020 Mar 11;21(6):1907. doi: 10.3390/ijms21061907. Int J Mol Sci. 2020. PMID: 32168769 Free PMC article. Review.
[Hepatocarcinogenesis in NASH].
Nakade Y, Sato K, Nakao H, Yoneda M. Nakade Y, et al. Among authors: yoneda m. Gan To Kagaku Ryoho. 2012 May;39(5):693-7. Gan To Kagaku Ryoho. 2012. PMID: 22584317 Review. Japanese.
Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Sumida Y, et al. Among authors: yoneda m. Diagnostics (Basel). 2020 Aug 10;10(8):579. doi: 10.3390/diagnostics10080579. Diagnostics (Basel). 2020. PMID: 32785100 Free PMC article. Review.
Correction to: The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.
Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A, Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). Ishiba H, et al. Among authors: yoneda m. J Gastroenterol. 2018 Nov;53(11):1225. doi: 10.1007/s00535-018-1478-7. J Gastroenterol. 2018. PMID: 29802457
206 results